SEC Form 4 · accession 0001209191-19-011362
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
Feb 14, 2019
Accepted (ET)
Feb 19, 2019 · 7:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 14, 2019 | M | 47,900 | $17.18 | A | 164,882 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F3 | Feb 14, 2019 | S | 34,000 | $81.4608 | D | 130,882 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F4 | Feb 14, 2019 | S | 13,900 | $82.2984 | D | 116,982 | I | Held by the Popovits 2010 Trust |
| Common StockF5 | holding | — | — | — | 68,028 | D | ||
| Common Stock | holding | — | — | — | 12,298 | I | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $17.18 | Feb 14, 2019 | M | 47,900 | D | — | Feb 18, 2020 | Common Stock | 47,900 | 0 | D |
Explanation of responses
- F1These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 17, 2018.
- F2Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F3Represents weighted average sale price. Actual sale prices ranged from $81.05 to $82.045.
- F4Represents weighted average sale price. Actual sale prices ranged from $82.06 to $82.83.
- F5Includes an aggregate of 62,164 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F6The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.